Target intelligence / Profile preview

Proteolipid protein 2 (PLP2)

Target
PLP2
Molecular classification
Integral membrane protein, Ion channel, Other (MARVEL domain-containing protein)
01

Overview

Proteolipid protein 2 (PLP2) is an integral multi-pass membrane protein primarily localized to the endoplasmic reticulum of colonic epithelial cells, enriched especially in the colonic mucosa. It can multimerize, contains a MARVEL domain (often found in proteins involved in membrane apposition), and is proposed to function as an ion channel. PLP2 may play a role in cell differentiation within the intestinal epithelium, apoptosis, autophagy, inflammation, and other cellular processes. Increased PLP2 expression has been observed in several cancers and is associated with disease progression, particularly in high-grade gliomas where it serves as a prognostic marker. A promoter polymorphism may be linked to X-linked cognitive disability, and the gene has a pseudogene on chromosome 5. No approved pharmaceuticals are described as direct interactors, though its manipulation by genetic or pharmacological means has shown effects on cell death and tumor growth in research models.

Other names
A4A4LSBA4 differentiation-dependent proteindifferentiation-dependent protein A4intestinal membrane A4 proteinproteolipid protein 2 (colonic epithelium-enriched)MGC126187
02

Mechanism of action

No approved drugs targeting PLP2 directly; for research, knockdown increases ER stress-induced apoptosis and autophagy.

03

Biological functions

Ion transportCell differentiation (intestinal epithelium)ApoptosisAutophagyInflammationCell proliferation
04

Disease associations

Cancer (including glioblastoma, melanoma, and breast adenocarcinoma)X-linked cognitive disabilityCold-Induced Sweating Syndrome 1Other (ER stress-related apoptosis)
05

Safety considerations

Therapeutic targeting may affect normal ion channel functions and risk off-target effects in colonic epithelium or neural tissue, but no direct clinical safety data are reported
06

Biomarkers

Increased expression of PLP2 is a biomarker for aggressive tumor behavior and poorer prognosis in gliomashigher PLP2 correlates with high-grade gliomas

Beyond the preview

Go deeper on Proteolipid protein 2 (PLP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteolipid protein 2 (PLP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call